T1	Disorder 22 46	nasal septal perforation
N1 	Reference T1 UMLS:C0235761	nasal septal perforation
T2	Pharmacological_substance 52 66	antiangiogenic
N1000 	Reference T2 MeSH:D020533	antiangiogenic
T3	Pharmacological_substance 67 78	bevacizumab
N1001 	Reference T3 MeSH:D000068258	bevacizumab
T4	Disorder 148 173	nasal septal perforations
N2 	Reference T4 UMLS:C0235761	nasal septal perforations
T5	Disorder 242 254	malignancies
N3 	Reference T5 UMLS:C0006826	malignancies
T6	Disorder 330 354	nasal septal perforation
N4 	Reference T6 UMLS:C0235761	nasal septal perforation
T7	Pharmacological_substance 371 390	antiangiogenic drug
T8	Pharmacological_substance 392 403	bevacizumab
N1002 	Reference T8 MeSH:D000068258	bevacizumab
T9	Disorder 409 434	metastatic ovarian cancer
T10	Pharmacological_substance 446 457	Bevacizumab
N1003 	Reference T10 MeSH:D000068258	Bevacizumab
T13	Disorder 775 800	nasal septal perforations
N5 	Reference T13 UMLS:C0235761	nasal septal perforations
T12	Pharmacological_substance 482 501	monoclonal antibody
N1004 	Reference T12 MeSH:D000911	monoclonal antibody
T18	Subject 278 301	52-year-old white woman
T14	Pharmacological_substance 205 219	antiangiogenic
N1005 	Reference T14 MeSH:D020533	antiangiogenic
T21	Disorder 570 582	angiogenesis
